Argenx Se Is A Global Immunology Company Founded In 2008 And Based In Amsterdamnetherlandswith Additional Offices In The U S Japanswitzerlandand Belgiumthe Company Focuses On Developing Human Antibody Therapies For Autoimmune Diseasesutilizing Proprietary Platforms To Enhance Antibody Functionality And Streamline Development One Of Its Key Products Is Vyvgarta Efgartigimod An Fcrn Blocker Approved For Treating Generalized Myasthenia Gravis In Adultsthe Company Has A Robust Pipeline That Includes Therapies For Various Conditions Such As Congenital Myasthenic Syndromechronic Inflammatory Demyelinating Polyneuropathyand Inflammatory Neuropathiesargenx Emphasizes Collaboration And Innovationaiming To Address Unmet Medical Needs In Immunology Through Its Advanced Research And Development Strategies
United States
